338 related articles for article (PubMed ID: 291066)
1. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.
Le Breton GC; Venton DL; Enke SE; Halushka PV
Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
[TBL] [Abstract][Full Text] [Related]
3. The thromboxane antagonist, 13-azaprostanoic acid, inhibits arachidonic acid-induced Ca2+ release from isolated platelet membrane vesicles.
Rybicki JP; Venton DL; Le Breton GC
Biochim Biophys Acta; 1983 Mar; 751(1):66-73. PubMed ID: 6830832
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR
Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599
[TBL] [Abstract][Full Text] [Related]
5. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
[TBL] [Abstract][Full Text] [Related]
6. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
Patscheke H; Stegmeier K
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():371-3. PubMed ID: 3159225
[No Abstract] [Full Text] [Related]
7. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
8. Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes.
Hung SC; Ghali NI; Venton DL; Le Breton GC
Biochim Biophys Acta; 1983 Feb; 728(2):171-8. PubMed ID: 6219702
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
10. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
[TBL] [Abstract][Full Text] [Related]
12. 2-(6-carboxyhexyl)cyclopentanone hexylhydrazone: a potent inhibitor of the blood platelet cyclo-oxygenase.
Le Breton GC; Hung SC; Ghali NI; Venton DL
Prostaglandins; 1984 Apr; 27(4):543-51. PubMed ID: 6427851
[TBL] [Abstract][Full Text] [Related]
13. Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.
Parise LV; Venton DL; Le Breton GC
Thromb Res; 1982 Dec; 28(6):721-30. PubMed ID: 6301090
[TBL] [Abstract][Full Text] [Related]
14. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets.
Fitzpatrick FA; Bundy GL; Gorman RR; Honohan T
Nature; 1978 Oct; 275(5682):764-6. PubMed ID: 703845
[No Abstract] [Full Text] [Related]
15. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
Harris RH; Nichols R; Schmeling JW; Ramwell PW
Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
[No Abstract] [Full Text] [Related]
17. Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.
Connolly TM; Limbird LE
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5320-4. PubMed ID: 6577431
[TBL] [Abstract][Full Text] [Related]
18. Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane.
DiMinno G; Silver MJ; Cerbone AM; Riccardi G; Rivellese A; Mancini M; Thiagarajan P
Blood; 1985 Jan; 65(1):156-62. PubMed ID: 2981130
[TBL] [Abstract][Full Text] [Related]
19. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
